A multi-omics analysis reported that mutations in tumor protein p53 (TP53), breast cancer gene (BRCA2), and the cytokine pathway correlated with benefit from chemo-immunotherapy (chemo-IO), whereas Kirsten rat sarcoma (KRAS) G12D and at-rich interaction domain 1A (ARID1) loss-of-function mutations were associated with poorer clinical outcomes. The gene discussed is KRAS; the disease is cancer.